TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please no advertisers. This is a free site for all.
Thank you.


Saturday, December 10, 2011

DUODOPA WITH COMT INHIBITORS FOR PARKINSON'S DISEASE

10th December 2011 - New research

European Journal of Neurology [2011] Dec 5 [Epub ahead of print] (D.Nyholm, A.Johansson, H.Lennernäs, H. Askmark)

Duodopa is a combination of L-dopa and carbidopa in the form of a gel. It is administered throughout the day using a portable pump directly into the small intestine through a surgically placed tube. This ensures a flow of L-dopa that can be adjusted according to the person's needs. It enables more consistent plasma concentrations of L-dopa. The side effects of Duodopa are similar to those observed with oral administration of L-dopa and carbidopa.

COMT inhibitors (Catechol-O-methyltransferase inhibitors) may be used to decrease the need for L-dopa, because they reduce its breakdown. COMT inhibitors have already been successfully used orally as Stalevo, which is a combination of L-dopa and carbidopa (the same as Sinemet), plus a COMT inhibitor (Entacapone). So researchers have investigated whether COMT inhibitors can also be taken orally in order to reduce the L-dopa requirement used with Duodopa. Both major COMT inhibitors (entacapone and tolcapone) were tested. The additional oral use of either of the COMT inhibitors was found to reduce the need of L-dopa by 20%. They did this without altering plasma L-dopa concentrations, reducing symptoms, or by reducing "off" time.